ImmoTest-II™

Early Cancer Signal Screening

ImmoTest-II™ is an advanced blood-based screening test designed to detect early biological signals that may be associated with cancer-related activity in the body.

Many conventional cancer screening methods focus on visible tumours, imaging findings, or selected tumour markers. While these tools are important, they may not always capture early biological changes happening at the cellular and molecular level.

ImmoTest-II™ is designed to provide a deeper layer of insight by analysing the body’s biological response patterns and selected gene-expression signals. This helps medical professionals identify whether further cancer-related investigation may be required.

It is suitable for individuals who want a more proactive, advanced, and preventive approach to cancer-related screening.

WHAT IMMOTEST-II™ IS?

ImmoTest-II™ is an advanced cancer signal screening test performed using a blood sample.

It is designed to study how the body responds to cancer-related biological activity by analysing selected cellular and molecular patterns.

Rather than only checking one tumour marker, ImmoTest-II™ looks at a broader biological picture. It reviews selected gene-expression activities and response patterns that may indicate whether the body is showing early warning signals that require further medical attention.

ImmoTest-II™ helps detect early cancer-related signals in the body before a clearer clinical picture may appear.

It is not a standalone cancer diagnosis. It is a screening and investigation-support test that helps doctors decide whether further medical evaluation, imaging, or specialist review may be needed.

HOW IMMOTEST-II™ WORKS?

The process starts with a blood sample.

From the sample, selected blood components are analysed to study cellular response and gene-expression activity. These biological signals are then reviewed to identify whether the pattern appears normal or suggests possible cancer-related activity.

ImmoTest-II™ may assess pathways related to:

• Cell growth and regulation
• Abnormal cellular signalling
• Inflammation-related response
• Cell repair mechanisms
• Cell survival pathways
• Blood vessel formation activity
• Stress-response patterns
• Cancer-related molecular activity

The goal is to identify whether the body is showing a concerning biological response that should be investigated further.

WHAT MAKES IMMOTEST-II™ DIFFERENT?

• Early Signal Screening
  • ImmoTest-II™ is designed to identify early biological patterns that may require further cancer-related investigation.
• Goes Beyond Routine Tumour Markers
  • It does not depend only on conventional tumour marker readings. It reviews broader cellular and molecular response patterns.
• Blood-Based Testing
  • The test is performed using a blood sample, making it convenient for advanced screening and preventive health programs.
• Supports Preventive Health Planning
  • ImmoTest-II™ can be included as part of executive screening, longevity programs, and proactive health monitoring.
• Guides Next-Step Investigation
  • The result may help doctors decide whether imaging, specialist consultation, repeat testing, or further diagnostic workup is needed.
• Suitable for High-Risk Individuals
  • It may be useful for individuals with family history of cancer, unexplained health concerns, or those seeking deeper preventive screening.

KEY BENEFITS

• Detects Early Biological Signals
  • Helps identify whether the body is showing cancer-related biological patterns that may require medical attention.
• Provides Deeper Insight Than Basic Screening
  • Goes beyond routine blood tests and isolated tumour markers.
• Supports Early Investigation
  • Helps guide whether further medical evaluation, imaging, or specialist review should be considered.
• Useful for Preventive Health Programs
  • Can be incorporated into executive wellness, longevity, and advanced health screening packages.
• Helps Doctors Make Better Decisions
  • Provides additional biological information to support professional interpretation and next-step planning.
• Supports Personalized Monitoring
  • May help create a more tailored screening and monitoring approach based on the individual’s biological profile.

WHO IMMOTEST-II™ IS DESIGNED FOR?

ImmoTest-II™ is designed for individuals who want a more advanced cancer-related screening approach.

It may be considered for those who:

• Want deeper cancer-related screening
• Have a family history of cancer
• Are undergoing executive health screening
• Want proactive preventive health monitoring
• Have unexplained symptoms that require further investigation
• Want more information beyond routine tumour markers
• Are advised by a doctor to undergo deeper biological screening
• Are enrolled in longevity or premium wellness programs

ImmoTest-II™ is suitable for people who want early biological insight, but it must always be interpreted by qualified healthcare professionals.

WHEN IMMOTEST-II™ MAY BE RECOMMENDED?

ImmoTest-II™ may be considered as part of:

• Annual advanced health screening
• Executive health screening
• Preventive cancer-related screening
• Family-history-based monitoring
• Longevity and wellness programs
• Doctor-led investigation planning
• Premium health assessment packages
• Follow-up screening where deeper biological insight is needed

It may also be recommended when routine screening results are unclear, or when the doctor wants an additional layer of biological information before deciding the next step.

WHAT THE RESULT MAY SHOW?

ImmoTest-II™ may indicate whether the body is showing a normal or concerning biological response pattern.

A concerning result does not automatically mean cancer is confirmed.

It may suggest that further investigations should be considered, such as:

• Imaging
• Specialist consultation
• Additional blood tests
• Organ-specific screening
• Repeat testing
• Closer medical monitoring
• Further diagnostic workup

The result should always be reviewed together with the patient’s medical history, symptoms, physical examination, imaging, laboratory findings, and doctor’s assessment.

HOW IMMOTEST-II™ SUPPORTS EARLY INVESTIGATION?

Early cancer-related changes may not always be visible through imaging or obvious symptoms.

ImmoTest-II™ supports early investigation by looking at biological response patterns that may appear before a clear diagnosis is made.

This allows the doctor to take a more proactive approach when something appears unusual.

The test does not replace standard screening, imaging, or specialist assessment. Instead, it adds another layer of insight to help guide a more complete evaluation.

SAMPLE AND PROFESSIONAL WORKFLOW

ImmoTest-II™ is performed through a professional blood collection process.

The general workflow may include:

1. Doctor consultation and suitability review
2. Blood sample collection
3. Laboratory analysis
4. Biological response and gene-expression review
5. Report generation
6. Doctor-led interpretation
7. Recommendation for further investigation, if required

The test result should not be interpreted alone. It should be assessed together with the patient’s overall clinical condition and relevant medical findings.

IMPORTANT NOTICE

ImmoTest-II™ is a screening and investigation-support test. It is not intended to independently diagnose cancer, treat cancer, cure cancer, or prevent cancer.

A concerning result does not confirm cancer. Further medical evaluation may be required.

Results must be interpreted by qualified medical professionals and reviewed together with the patient’s symptoms, medical history, imaging, laboratory findings, and overall clinical condition.